# Kim Jaffe

> Kim Jaffe, PhD, is Chief Business Officer at BlueSphere Bio, a Pittsburgh-based clinical-stage biotech building personalized T-cell receptor therapies for cancer using its TCXpress discovery platform. A bench scientist turned dealmaker, she trained in cell and molecular biology at Northwestern and Princeton, ran cell-line development and R&D at clinical-stage oncology companies, and now leads strategy, partnerships, and business development as the company pushes TCR T-cell candidates toward high-risk leukemias.

- **Role:** Chief Business Officer at BlueSphere Bio
- **Organizations:** BlueSphere Bio, OncoSec Immunotherapies, Advaxis, Inc., Oncobiologics Inc.
- **Nationality:** American
- **Education:** B.S. in Cell and Structural Biology, minor in Chemistry, University of Illinois at Urbana-Champaign, PhD in Biochemistry, Cell Biology, and Molecular Biology, Northwestern University, Postdoctoral training in Cell and Molecular Biology, Princeton University
- **Known for:** Advanced two neoantigen therapies to clinical stage at Advaxis, Led cell-line development and contributed to regulatory filings at Oncobiologics, Earned a PhD spanning biochemistry, cell biology, and molecular biology at Northwestern University

## Career timeline

- **2008-2011** — Postdoctoral Fellow at Princeton University, studying left-right patterning in early development using zebrafish
- **2011-2017** — Principal Scientist / head of cell line development at Oncobiologics Inc., contributing to early development of biosimilar programs
- **2017-2019** — Senior Director of Research at Advaxis, Inc.; advanced two neoantigen therapies to clinical stage, later head of R&D
- **2019-2020** — Senior Director of Business Development and Project Management at OncoSec Immunotherapies
- **2020-2021** — Associate Vice President of Business Development & Operations at OncoSec
- **2021** — Joined BlueSphere Bio as Senior Vice President, Head of Business Development & Strategy
- **Present** — Chief Business Officer at BlueSphere Bio

## Achievements

- Advanced two neoantigen therapies to clinical stage at Advaxis
- Led cell-line development and contributed to regulatory filings at Oncobiologics
- Earned a PhD spanning biochemistry, cell biology, and molecular biology at Northwestern University
- Completed postdoctoral training at Princeton University
- Built and led business development and strategy function at BlueSphere Bio as it advances TCR T-cell therapies toward the clinic

## Latest updates

- **2021-01** — Joined BlueSphere Bio as Senior Vice President, Head of Business Development & Strategy

## Links

- Website: https://bluespherebio.com
- LinkedIn: http://www.linkedin.com/in/kim-jaffe-14210240

---

Profile page: https://yespress.io/kim-jaffe
Published by YesPress — https://yespress.io
Last updated: 2026-06-03